New study finds genetic alterations in the VAC14 gene are associated with an increased risk of docetaxel-induced peripheral neuropathy in prostate cancer patients
New study finds genetic alterations in the VAC14 gene are associated with an increased risk of docetaxel-induced peripheral neuropathy in prostate cancer patients.
Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers from Moffitt Cancer Center report prostate cancerpatients who have a variation in the VAC14 gene are more susceptible to a side effect called peripheral neuropathy when treated with the taxane docetaxel.
https://clincancerres.aacrjournals.org/content/early/2016/05/03/1078-0432.CCR-15-2823TR
Comments
Post a Comment